Life ScienceCompany
Vertex Pharmaceuticals M&A Summary
Vertex Pharmaceuticals has acquired 8 companies, including 5 in the last 5 years. A total of 1 acquisition came from private equity firms. It has also divested 2 assets.
Vertex Pharmaceuticals’ largest acquisition to date was in 2024, when it acquired Alpine Immune Sciences for $4.9B. It’s largest disclosed sale occurred in 2013, when it sold INCIVO to Janssen Pharmaceuticals for $152M. Vertex Pharmaceuticals has acquired in 3 different US states, and 2 countries. The Company’s most targeted sectors include life science (100%).
Vertex Pharmaceuticals Business Overview
Where is Vertex Pharmaceuticals headquartered?
Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
What is Vertex Pharmaceuticals’ revenue?
Vertex Pharmaceuticals disclosed revenue of 9,869M USD for 2023 and 8,931M USD for 2022.
How many employees does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 5,400 employees.
What sector is Vertex Pharmaceuticals in?
Vertex Pharmaceuticals is a life science company.
When was Vertex Pharmaceuticals founded?
Vertex Pharmaceuticals was founded in 1989.
M&A Summary
-
M&A Total Activity10
- M&A Buy Activity8
- M&A Sell Activity2
- Total Sectors Invested 1
- Total Countries Invested 2
- M&A Buy/Sell Connections 4
- M&A Advisors 2
Unlimited Searches
